Company intelligence / Profile preview

Braxia Health

Toronto, Ontario, Canada

Ownership: Private
Employees: ~50
Development stage: Other

Overview

Braxia Health has demonstrated significant clinical results with rapid-acting antidepressant modalities like intravenous ketamine and intranasal esketamine, showing symptom improvement within 24 hours for treatment-resistant depressive disorders. It is a pioneer in Canadian regulatory trials for psilocybin derivatives, and operates the largest clinic-based research program for these modalities, with over 3,000 IV ketamine infusions and 345 intranasal/sublingual treatments administered to date[2][5].

Therapeutic areas: Psychiatry
Modalities: Small molecule (for ketamine, esketamine)Psychedelic derivative
Industry: Biotech

Partnerships

Irwin Naturals (for human clinical studies in the U.S. supporting pharmaceutical partnerships)[4]

Beyond the preview

Go deeper on Braxia Health.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Braxia Health.

Explore the full profile